Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
05:00pm, Tuesday, 25'th Feb 2025
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engi
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
08:00am, Monday, 24'th Feb 2025
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has comple
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab
09:00am, Friday, 21'st Feb 2025
BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecuri
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public h
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
08:00am, Wednesday, 19'th Feb 2025
STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation
08:00am, Tuesday, 18'th Feb 2025
Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the
DNA from Fiserv Selected by Third Federal as Part of its Digital Transformation
09:42am, Friday, 14'th Feb 2025
MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced it will deliver digital innovation through the award-winni
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
04:03pm, Thursday, 13'th Feb 2025
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified fo
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
12:00pm, Wednesday, 12'th Feb 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polym
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
08:30am, Tuesday, 11'th Feb 2025
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to it
Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podca
Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?
09:25am, Thursday, 06'th Feb 2025
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series
08:01am, Thursday, 06'th Feb 2025
Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity,
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
08:00am, Wednesday, 05'th Feb 2025
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatm
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 29'th Jan 2025
Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
